Correlations between serum cetuximab and EGFR-related markers, and skin disorders in head and neck cancer patients.

Head and neck cancer patients with a higher serum IL-6 level tended to have a lower serum cetuximab level. Serum cetuximab had positive correlations to skin rash severity and its medication in the study population.